Compare
QHSLab, Inc. vs OSR Health, Inc. vs Femasys Inc vs Nuo Therapeutics, Inc.
| Latest fiscal year | QHSLab, Inc. USAQ | OSR Health, Inc. OSRH | Femasys Inc FEMY | Nuo Therapeutics, Inc. AURX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.69M | $2.91M | $2.29M | $3.31M |
| Revenue growth (YoY) | +26.3% | -17.7% | +40.8% | +142.7% |
| Gross margin | 67.3% | 20.4% | 62.0% (computed) | 66.9% |
| Operating margin | 4.9% | -631.0% | -767.0% | -76.0% |
| Net margin | 17.0% | -931.2% | -812.3% | -75.8% |
| Net income | $457.4K | -$27.06M | -$18.63M | -$2.51M |
| EPS (Diluted) | $0.02 | -$0.80 | -$0.47 | n/a |
| Operating cash flow | $178.1K | -$4.33M | -$18.69M | -$865.0K |
| Free cash flow | n/a | n/a | -$19.22M | -$1.14M |
| Cash & equivalents | $636.2K | $1.70M | $9.27M | $548.9K |
| Total assets | $2.17M | $171.24M | $20.72M | $1.85M |
| Total liabilities | $546.1K | $44.20M | $14.85M | $2.80M |
| Shareholders' equity | $1.62M | $127.04M | $5.87M | -$956.6K |
| Return on year-end equity | 28.1% | -21.3% | -317.4% | n/a |
| Shares outstanding | 15.03M | 26.60M | 59.60M | 48.18M |
Revenue, most recent five fiscal years
| Fiscal year | QHSLab, Inc. | OSR Health, Inc. | Femasys Inc | Nuo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $2.69M Ended 2025-12-31 | $2.91M Ended 2025-12-31 | $2.29M Ended 2025-12-31 | $3.31M Ended 2025-12-31 |
| 1 year earlier | $2.13M Ended 2024-12-31 | $3.53M Ended 2024-12-31 | $1.63M Ended 2024-12-31 | $1.37M Ended 2024-12-31 |
| 2 years earlier | $1.41M Ended 2023-12-31 | n/a | $1.07M Ended 2023-12-31 | $608.5K Ended 2023-12-31 |
| 3 years earlier | $1.24M Ended 2022-12-31 | n/a | $1.21M Ended 2022-12-31 | $112.2K Ended 2022-12-31 |
| 4 years earlier | $1.41M Ended 2021-12-31 | n/a | $1.18M Ended 2021-12-31 | $0 Ended 2021-12-31 |